Payment & Shipping Terms:
|Product Name:||Lenvatinib||Advantages:||Reship Policy|
|Suitable For:||Adult||Type:||Pharmaceutical Intermediate|
|Appearance:||White Powder||Purity:||98% Min|
Pharma Raw Materials,
|Synonyms:||4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide;E7080;E7080 (Lenvatinib);Lenvatinib (E7080);ER-203492-00;1-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea;4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide XEN445;E70801-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea|
|Product Categories:||-;FGF receptor antagonist;Inhibitors|
Lenvatinib is a thyroid cancer drug developed by Eisai Corporation of Japan (Code: E7080), belonging to the inhibitor of oral multi-receptor tyrosine kinase (RTK) and can inhibit the kinase activity of the vascular endothelial growth factor (VEGF) Receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib can also inhibit the involvement of other RTKs in pathological angiogenesis, tumor growth, and cancer progression except for their normal cellular functions including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-derived growth factor receptor (PDGFR [alpha]), KIT, and RET.
[Indications]: Lenvatinib is suitable for the treatment of patients of thyroid cancer of local recurrence or metastasis type, progressivity type and radioactive iodine-refractory differentiated type.
On February 13, 2015, the US FDA approved anticancer drug Lenvatinib for the treatment of thyroid cancer. Lenvatinib is a multi-target enzyme inhibitor, being capable of inhibiting the VEGFR2 and VEGFR3 (vascular endothelial growth factor receptor). The trade name of Lenvatinib is Lenvima.
On May 20, 2015, the European Medicines Agency (EMA) approved Lenvatinib for the treatment of invasive, locally advanced or metastatic differentiated (papillary, follicular, Hurthle type) thyroid cancer (DTC). In the trial, the median survival time for patients of radioactive iodine-refractory DTC treated with Lenvatinib was 18 months while the value for patients who take placebo is only 3 months.
In Europe, Lenvatinib will compete with Bayer's kinase inhibitor sorafenib (trade name: Nexavar), which had been respectively approved by EMA and the US Food and Drug Administration for the treatment of radioactive iodine refractory DTC in 2014 and 2013, respectively. At the time, Sorafenib had been reported to be the first targeted therapeutics to be marketed for the past 40 years in the treatment of refractory DTCs. The marketing applications of Lenvatinib in Switzerland, South Korea, Canada, Singapore, Russia, Australia and Brazil are also under review.
Information regarding the pharmacological effects, clinical evaluation, and indication of the thyroid cancer drug Lenvatinib were compiled and edited by Tongtong from Chemicalbook (2015-09-22)
E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.
other product :
|Sustanon-250||Testosterone Sustanon 250mg/ml|
|Sustanon-450||Testosterone Sustanon 450mg/ml|
|Test-100||Testosterone Base 100mg/ml|
|Test-150||Testosterone Base 150mg/ml|
|TA-100||Testosterone Acetate 100mg/ml|
|TD-250||Testosterone Decanoate 250mg/ml|
|TE-250||Testosterone Enathate 250mg/ml|
|TE-300||Testosterone Enathate 300mg/ml|
|TE-600||Testosterone Enathate 600mg/ml|
|TC-250||Testosterone Cypionate 250mg/ml|
|TREN-A80||Trenbolone Acetate 80mg/ml|
|TREN-A100||Trenbolone Acetate 100mg/ml|
|TREN-E100||Trenbolone Enanthate 100mg/ml|
|TREN-E200||Trenbolone Enanthate 200mg/ml|
|TRH-75||Trenbolone Hexahydrobenzyl 75mg/ml|
|PRIMO-100||Methenolone Enanthate 100mg/ml|
|NPP-100||Nandrolone Phenyl Propionate 100mg/ml|
|NPP-200||Nandrolone Phenyl Propionate 200mg/ml|
|NPP-250||Nandrolone Phenylpropionate 250mg/ml|
|DECA-200 (ND-200)||Nandrolone Decanoate 200mg/ml|
|DECA-300 (ND-300)||Nandrolone Decanoate 300mg/ml|
|BC-200||Boldenone Cypionate 200mg/ml|
|BC-300||Boldenone Cypionate 300mg/ml|
|BOLDEN-300||Boldenone Undecylenate 300mg/ml|
|BOLDEN-600||Boldenone Undecylenate 600mg/ml|
|Masteron P-100||Drostanolone Propionate 100mg/ml|
|Masteron P-50(MCT oil)||Drostanolone Propionate 50mg/ml|
|Masteron E-100||Drostanolone Enathate 100mg/ml|
|Anadrol 20(oil)||Anadrol 20mg|
we, Yihan Industrial Co., Ltd from china are specilized in steroids powder , semi-finished liquids , peptides , Sarm powder,HGH,HCG,Finished Liquid and other pharmaceutical materials for many years .
If you have any further questions or need a sample,Please do not hesitate to contact me.Thank you!